Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AAV5-hRKp.RPGR

Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx Ocular UK

Phase 3 Most advanced trial (none active)
MGTX Developer
1 Registered trials

What is AAV5-hRKp.RPGR?

AAV5-hRKp.RPGR is an adeno-associated virus serotype 5 gene therapy carrying the human RPGR gene, delivered by sub-retinal injection. It is being studied in X-linked retinitis pigmentosa, an inherited retinal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Ophthalmology
Developer
MeiraGTx Ocular UK Ltd (MGTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04671433 Phase 3 X-Linked Retinitis Pigmentosa Completed MGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

X-Linked Retinitis Pigmentosa

More from MeiraGTx Ocular UK

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.

Follow MGTX, the company behind AAV5-hRKp.RPGR

See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.